• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Bullfrog AI Holdings Inc.

    8/15/24 4:59:48 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email
    S-3/A 1 forms-3a.htm

     

    As filed with the Securities and Exchange Commission on August 15, 2024.

     

    Registration No. 333-281341

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-3

    (Amendment No. 1)

    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933

     

    BULLFROG AI HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   84-4786155
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification Number)

     

    325 Ellington Blvd., Unit 317

    Gaithersburg, MD 20878

    (240) 658-6710

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

    Vininder Singh

    Chief Executive Officer

    Bullfrog AI Holdings, Inc.

    325 Ellington Blvd., Unit 317

    Gaithersburg, MD 20878

    (240) 658-6710

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Arthur S. Marcus, Esq.

    Sichenzia Ross Ference Carmel LLP

    1185 Avenue of the Americas, 31st Floor

    New York, New York 10036

    (212) 930-9700

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plants, check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

    The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    This Amendment to the Registration Statement on Form S-3 (File No. 333-281341) is filed solely to amend Item 16 of Part II thereof and to file a modified auditor’s consent as Exhibit 23.1. This Amendment does not modify any other provision of the preliminary prospectus contained in Part I, or Part II. Accordingly, the preliminary prospectus has been omitted.

     

    1

     

     

    Item 16. Exhibits.

     

    Exhibit    
    Number   Description of Document
    1.1   Form of Underwriting Agreement.*
    3.1   Amended and Restated Articles of Incorporation of Bullfrog AI Holdings, Inc. incorporated by reference to Exhibit 3.1 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
    3.2   Bylaws of Bullfrog AI Holdings, Inc. incorporated by reference to Exhibit 3.2 to the Company’s Amendment to the Registration Statement on Form S-1 (No. 333-267951) filed with the Securities and Exchange Commission on February 13, 2023.
    4.1   Form of Certificate of Designation.*
    4.2   Form of Preferred Stock Certificate.*
    4.3   Form of Warrant Agreement.*
    4.4   Form of Warrant Certificate.*
    4.5   Form of Stock Purchase Agreement.*
    4.6   Form of Unit Agreement.*
    5.1   Opinion of Sichenzia Ross Ference Carmel LLP.**
    23.1   Consent of M&K CPAs, PLLC.
    23.2   Consent of Sichenzia Ross Ference Carmel LLP (contained in Exhibit 5.1).**
    107   Filing Fee Table.**

     

    * To be filed by amendment or by a Current Report on Form 8-K and incorporated by reference herein.
    ** Previously filed

     

    II-1
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the amendment to Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, State of Maryland, on August 15, 2024.

     

      Bullfrog AI Holdings, Inc.
         
      By: /s/ Vininder Singh
        Vininder Singh
      Its: Chief Executive Officer
        (Principal Executive Officer)
         
      By: /s/ Dane Saglio
        Dane Saglio
      Its: Chief Financial Officer
        (Principal Financial and Accounting Officer)

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    /s/ Vininder Singh   August 15, 2024
    Vininder Singh    
    Chief Executive Officer and Director (Principal Executive Officer)    
         
    /s/ Dane Saglio   August 15, 2024
    Dane Saglio    

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

       
         
    /s/ *   August 15, 2024
    R. Donald Elsey    
    Director    
         
    /s/ *   August 15, 2024
    William Enright    
    Director    
         
    /s/ *   August 15, 2024
    Jason D. Hanson    
    Director    
         
    * /s/ Vininder Singh    
    Vininder Singh    
    Attorney-in-Fact    

     

    II-2

     

    Get the next $BFRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hanson Jason David

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:16:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Enright William

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:14:44 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Elsey R Don

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:12:13 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BullFrog AI to Unveil New Precision AI Capability

    New capabilities to be launched on March 25Unique technology bolsters BullFrog AI's end-to-end AI intelligence workflow with a scenario-based decision engineAdvances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design

    2/4/26 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

    GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, "Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences," with a discussion on how BullFrog AI's bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development. "The rush to apply AI in biopharma drug de

    1/27/26 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

    DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms. Alumis (NASDAQ:ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week 24,

    1/6/26 9:30:40 AM ET
    $ALMS
    $BFRG
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    SEC Filings

    View All

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    12/30/25 5:00:50 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Bullfrog AI Holdings Inc.

    424B3 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    12/1/25 4:30:18 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Bullfrog AI Holdings Inc.

    EFFECT - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    11/26/25 12:15:32 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Financials

    Live finance-specific insights

    View All

    BullFrog AI and GreenPower Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u

    4/26/24 9:00:00 AM ET
    $BFRG
    $GP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto

    10/27/23 9:00:00 AM ET
    $ASPI
    $BFRG
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Announces Appointment of Chief Financial Officer

    GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and

    12/17/24 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

    GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea

    10/15/24 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care